COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, COVID-19 vaccine, cohort study, vaccine effectiveness, close contact, 【초록키워드】 Vaccine, vaccination, SARS-COV-2 infection, infections, symptomatic, Effectiveness, symptomatic infection, dose, Support, hospitalisations, second dose, finding, COVID-19 hospitalisation, Complete, significantly increased, diagnosed, evaluated, 【제목키워드】 SARS-COV-2 infection, Spain, hospitalisation,
【저자키워드】 COVID-19, SARS-CoV-2, COVID-19 vaccine, cohort study, vaccine effectiveness, close contact, 【초록키워드】 Vaccine, vaccination, SARS-COV-2 infection, infections, symptomatic, Effectiveness, symptomatic infection, dose, Support, hospitalisations, second dose, finding, COVID-19 hospitalisation, Complete, significantly increased, diagnosed, evaluated, 【제목키워드】 SARS-COV-2 infection, Spain, hospitalisation,